Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ...
BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors, today ...
Abpro successfully closed a business combination with Atlantic Coastal Acquisition Corp II, marking a significant milestone in its journey to provide advanced antibody therapies. The company raised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results